Indication BioScience
Clinical-stage biopharmaceutical company developing fixed-dose combination therapies for cardiovascular and metabolic disease. The company’s Statin+ platform combines well-characterized statins with complementary small molecules to preserve established LDL-cholesterol lowering while aiming to improve tolerability and long-term treatment persistence. Activities include preclinical evaluation, early-phase clinical trials, translational biomarker analysis, regulatory engagement, and maintenance of an intellectual property portfolio covering formulation and combination approaches.
Industries
Nr. of Employees
medium (51-250)
Indication BioScience
Patents
Compositions and methods using a cannabinoid to enhance bioavailability of a statin
US-11786482-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-11234944-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-10835501-B2
View Details
Compositions and methods using a cannabinoid to enhance bioavailability of a statin
US-11786482-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-11234944-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-10835501-B2
View DetailsProducts
Atorvo+ (ATO-875)
Investigational oral fixed-dose combination pairing atorvastatin with a complementary small molecule formulated as an orally active solid form to preserve LDL-C lowering while exploring improved tolerability.
Statin+ platform
Platform framework for repeatable development of statin-based fixed-dose combinations using a consistent formulation, IP, and regulatory strategy to scale across multiple statins.
Atorvo+™
Atorvo+™ combines atorvastatin with a proprietary, well-characterized small molecule in a rationally designed fixed-dose formulation to preserve lipid-lowering efficacy while improving long-term tolerability and adherence.
Lova+
A fixed-dose combination therapy in the Statin+ pipeline pairing lovastatin with a complementary small molecule.
Rosova+
A fixed-dose combination therapy in the Statin+ pipeline pairing rosuvastatin with a complementary small molecule.
Simva+
A fixed-dose combination therapy in the Statin+ pipeline pairing simvastatin with a complementary small molecule.
Atorvo+ (ATO-875)
Investigational oral fixed-dose combination pairing atorvastatin with a complementary small molecule formulated as an orally active solid form to preserve LDL-C lowering while exploring improved tolerability.
Statin+ platform
Platform framework for repeatable development of statin-based fixed-dose combinations using a consistent formulation, IP, and regulatory strategy to scale across multiple statins.
Atorvo+™
Atorvo+™ combines atorvastatin with a proprietary, well-characterized small molecule in a rationally designed fixed-dose formulation to preserve lipid-lowering efficacy while improving long-term tolerability and adherence.
Lova+
A fixed-dose combination therapy in the Statin+ pipeline pairing lovastatin with a complementary small molecule.
Rosova+
A fixed-dose combination therapy in the Statin+ pipeline pairing rosuvastatin with a complementary small molecule.
Simva+
A fixed-dose combination therapy in the Statin+ pipeline pairing simvastatin with a complementary small molecule.
Services
Design and execution support for early-phase clinical programs, regulatory engagement planning, and endpoint selection.
Design and execution support for early-phase clinical programs, regulatory engagement planning, and endpoint selection.
Expertise Areas
- Fixed-dose combination drug development
- Early-phase clinical trial management
- Clinical pharmacology and pharmacokinetics
- Translational biomarker development
Key Technologies
- Proteomics
- Pharmacokinetic (PK) studies
- Mitochondrial stress assays
- Oral solid formulation development
News & Updates
Announcement of successful completion of randomized Phase 1 PK and safety study showing acceptable safety, tolerability, and a characterized pharmacokinetic interaction versus statin monotherapy.
Early Phase I findings including proteomic results and exploratory biomarker data suggesting engagement of pathways linked to muscle and metabolic side effects.
Company received FDA written responses after a Type B Pre-IND meeting and is incorporating recommendations into Phase II program design.
Announcement of partnership with an early-phase clinical research organization to conduct the first-in-human study, including incorporation of proteomics and mitochondrial stress assays.
Issuance of U.S. Patent US10835501B2 covering statin-cannabinoid combination compositions and uses.
Announcement of appointment of Chief Medical Officer and his role in shaping clinical development for the fixed-dose combination program.
Announcement of successful completion of randomized Phase 1 PK and safety study showing acceptable safety, tolerability, and a characterized pharmacokinetic interaction versus statin monotherapy.
Early Phase I findings including proteomic results and exploratory biomarker data suggesting engagement of pathways linked to muscle and metabolic side effects.
Company received FDA written responses after a Type B Pre-IND meeting and is incorporating recommendations into Phase II program design.
Announcement of partnership with an early-phase clinical research organization to conduct the first-in-human study, including incorporation of proteomics and mitochondrial stress assays.
Issuance of U.S. Patent US10835501B2 covering statin-cannabinoid combination compositions and uses.
Announcement of appointment of Chief Medical Officer and his role in shaping clinical development for the fixed-dose combination program.